Allakos (NASDAQ:ALLK) Issues Quarterly Earnings Results

Allakos (NASDAQ:ALLKGet Rating) posted its quarterly earnings data on Thursday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.04), Fidelity Earnings reports.

Allakos Stock Performance

Shares of NASDAQ ALLK opened at $3.99 on Friday. The stock’s fifty day moving average is $3.31 and its 200 day moving average is $4.55. Allakos has a 52 week low of $2.54 and a 52 week high of $11.73.

Institutional Trading of Allakos

Several large investors have recently bought and sold shares of ALLK. Swiss National Bank boosted its stake in Allakos by 8.1% in the first quarter. Swiss National Bank now owns 77,100 shares of the company’s stock valued at $439,000 after buying an additional 5,800 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Allakos by 258.1% in the first quarter. JPMorgan Chase & Co. now owns 535,368 shares of the company’s stock valued at $3,052,000 after buying an additional 385,878 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Allakos by 27.7% in the first quarter. Bank of New York Mellon Corp now owns 181,550 shares of the company’s stock valued at $1,034,000 after buying an additional 39,395 shares in the last quarter. BlackRock Inc. boosted its stake in Allakos by 8.4% in the first quarter. BlackRock Inc. now owns 2,911,899 shares of the company’s stock valued at $16,599,000 after buying an additional 226,498 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in Allakos in the first quarter valued at about $1,077,000. 61.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Allakos in a research report on Monday, May 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $66.80.

About Allakos

(Get Rating)

Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.

Recommended Stories

Earnings History for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.